Related Experiment Video
Updated: Mar 24, 2026
10:31
Antigenic Liposomes for Generation of Disease-specific Antibodies
Published on: October 25, 2018
12.9K
Pediatric Myasthenia Gravis
Andrew F Fischer1, Jason H Peragallo
1Department of Ophthalmology, Emory University School of Medicine, Atlanta, GA.
International Ophthalmology Clinics
|March 23, 2026
Summary
Pediatric myasthenia gravis, a neuromuscular junction disorder, presents with fatigable weakness. Diagnosis involves clinical, serologic, and electrophysiologic studies, with management including medications and thymectomy for juvenile cases.
Area of Science:
- Neurology
- Pediatrics
- Immunology
Background:
- Pediatric myasthenia gravis is a group of disorders affecting neuromuscular junction transmission.
- It causes fatigable weakness, potentially impacting respiration.
- Three subtypes exist: transient neonatal myasthenia, congenital myasthenic syndromes, and juvenile myasthenia gravis.
Purpose of the Study:
- To outline the diagnostic approaches and management strategies for pediatric myasthenia gravis.
- To differentiate between the subtypes of pediatric myasthenia gravis.
- To highlight the importance of managing ophthalmic complications.
Main Methods:
- Clinical evaluation.
- Serologic studies.
- Electrophysiologic studies.
Main Results:
- Diagnosis relies on a combination of clinical, serologic, and electrophysiologic findings.
- Management involves acetylcholinesterase inhibitors, immunosuppressive agents, thymectomy (for JMG), IVIG, and PLEX for exacerbations.
- Ophthalmic complications like strabismus and ptosis require management to prevent amblyopia.
Conclusions:
- Pediatric myasthenia gravis is a complex condition with distinct subtypes.
- Comprehensive diagnostic evaluation is crucial for appropriate treatment.
- Multifaceted management, including medical therapy and surgical options, is essential for optimal outcomes and preventing vision loss.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
3.4K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.4K
01:15Myasthenia Gravis: Diagnostic Tests
3.1K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.1K
01:28Disorders of the Skeletal Muscle
2.3K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
2.3K
01:26Chemical Synapses
12.4K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
12.4K
01:26Chemical Synapses
8.1K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
8.1K
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
322
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
322